MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.390
-0.030
-0.88%
Closed 16:00 09/24 EDT
OPEN
3.390
PREV CLOSE
3.420
HIGH
3.460
LOW
3.340
VOLUME
66.36K
TURNOVER
--
52 WEEK HIGH
13.50
52 WEEK LOW
3.120
MARKET CAP
109.07M
P/E (TTM)
-1.8907
1D
5D
1M
3M
1Y
5Y
We Think Concert Pharmaceuticals (NASDAQ:CNCE) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 4d ago
Concert Pharmaceuticals Sponsored Study Titled 'European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata' Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05041803
Benzinga · 09/13 13:42
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
LEXINGTON, Mass., September 03, 2021--In September, Concert will present virtually at the HC Wainwright and Cantor healthcare conferences.
Business Wire · 09/03 11:00
Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month
LEXINGTON, Mass., August 31, 2021--Landmarks across the USA will light it up blue for alopecia areata awareness month, which is recognized annually during September.
Business Wire · 08/31 11:00
Looking into Concert Pharmaceuticals's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Concert Pharmaceuticals (NASDAQ:CNCE) earned $6.22 million, a 125.93% increase from the preceding quarter.
Benzinga · 08/27 21:12
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 08/10 20:52
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CNCE. Analyze the recent business situations of Concert Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNCE stock price target is 15.33 with a high estimate of 22.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 119
Institutional Holdings: 21.26M
% Owned: 66.09%
Shares Outstanding: 32.17M
TypeInstitutionsShares
Increased
23
1.72M
New
14
679.70K
Decreased
31
3.95M
Sold Out
26
911.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Richard Aldrich
President/Chief Executive Officer/Co-Founder/Independent Director
Roger Tung
Chief Financial Officer
Marc Becker
Chief Operating Officer
Nancy Stuart
Other
James Cassella
Secretary
Jeffrey Munsie
Independent Director
Thomas Auchincloss
Independent Director
Ronald Barrett
Independent Director
Jesper Hoiland
Independent Director
Peter Hutt
Independent Director
Wilfred Jaeger
Independent Director
Christine Van Heek
No Data
  • All
  • Financials
  • Insiders
More
About CNCE
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.